Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease liver disease
Phenotype |obesity
Sentences 83
PubMedID- 26011302 Background: nonalcoholic fatty liver disease (nafld) is associated with obesity, type 2 diabetes mellitus, and dyslipidemia.
PubMedID- 22720311 Although obesity is closely associated with non-alcoholic fatty liver disease, the excess of visceral fat storage is reckoned to be just as or even more important.
PubMedID- 23951308 Nonalcoholic fatty liver disease is associated with obesity and insulin resistance.
PubMedID- 23256660 Elevated serum alt is a biomarker of hepatic injury, often caused by the nonalcoholic fatty liver disease associated with obesity and t2dm.
PubMedID- 22519397 Nonalcoholic fatty liver disease is associated with obesity and contributes to insulin resistance, and metformin is used to treat individuals with these conditions.
PubMedID- 24528352 Non alcoholic fatty liver disease (nafld) is associated with obesity, insulin resistance (ir) and increased type 2 diabetes (t2d).
PubMedID- 25733100 Our aim was to elucidate the effect and relationship between habitual alcohol intake and obesity in the development of fatty liver disease.
PubMedID- 25939720 Background: obesity is associated with non-alcoholic fatty liver disease (nafld), and the patatin-like phospholipase 3 (pnpla3) rs738409 (ile148met, c>g) gene polymorphism is one of the most important genetic determinants of nafld.
PubMedID- 24751397 Similar findings were observed by several other rodent studies [22,23] and have recently been confirmed in liver biopsies of patients with nafld, highlighting the clinical relevance of cd36 in human liver diseases associated with obesity and type 2 diabetes [24].
PubMedID- 23431426 Morbid obesity is strongly associated with nonalcoholic fatty liver disease (nafld) which is one of the most common causes of chronic liver disease worldwide.
PubMedID- 24339864 Considering that we observed significant sfrp1 dependent changes in the gluconeogenic transcripts in the liver, and non-alcoholic fatty liver disease is tightly associated with obesity and hyperglycemia [31], we chose to examine the effects of a hfd in the livers of these mice.
PubMedID- 20818807 Although it is well established that insulin resistance, glucose intolerance and obesity occur frequently with non-alcoholic fatty liver disease (nafld), it is now becoming apparent that hypoxia might also be important in the development of nafld, and it is recognized that there is increased risk of nafld with osa.
PubMedID- 25755500 Background: obesity increases the risk of fatty liver disease and liver cancer.
PubMedID- 21611179 Chronic liver disease associated with obesity has been identified in adults since 1970s and soon after this condition was also reported in childhood and adolescence [6], [7].
PubMedID- 20446347 Recent findings: obesity is associated with nonalcoholic fatty liver disease, dyslipidemia, hyperglycemia and type 2 diabetes.
PubMedID- 21757980 A reason for the prevalence and the social cost have not been declined despite the decrease of chronic viral hepatitis b, is considered to be caused by the increase of liver disease related with alcohol, obesity, and herb medicines and supplementary health food.
PubMedID- 25031864 Identified chronic liver disease associated with obesity in adults as a distinct entity (6).
PubMedID- 25514904 Excess accumulation of hepatic tg is a hallmark of nonalcoholic fatty liver disease, which is associated with obesity and insulin resistance.
PubMedID- 22201932 Non alcoholic fatty liver disease (nafld) is associated with obesity, diabetes and insulin resistance (ir).
PubMedID- 23661530 In most subjects liver diseases are self-limiting, associated with obesity, hormonal therapy and autoimmune diseases.
PubMedID- 24070151 According to the obesity trend, the prevalence of pediatric nonalcoholic fatty liver disease (nafld) is also increasing.
PubMedID- 23954639 Indeed, adipocytes from obese mice display elevated levels of p53 (yahagi et al., 2003), and liver p53 levels are induced in mouse models of hepatic steatosis (fatty liver disease) associated with obesity (yahagi et al., 2004) and chronic alcohol consumption (derdak et al., 2011).
PubMedID- 25456868 Nonalcoholic fatty liver disease (nafld) is associated with obesity and insulin resistance and has been linked with increased cardiovascular risk.
PubMedID- 23391869 Goals/background: nonalcoholic fatty liver disease (nafld) is associated with obesity, but it may also be present in lean individuals.
PubMedID- 21364120 Nonalcoholic fatty liver disease (nafld) is associated with obesity, insulin resistance, and inflammatory disorders.
PubMedID- 26325428 Nonalcoholic fatty liver disease (nafld), frequently associated with obesity and diabetes mellitus, is caused by the accumulation of excess fatty acids within liver cells.
PubMedID- 22468076 Nonalcoholic fatty liver disease (nafld) is associated with obesity, insulin resistance, and type 2 diabetes.
PubMedID- 21604917 Hepatic steatosis due to non-alcoholic fatty liver disease is associated with obesity, dyslipidemia, insulin resistance, and type 2 diabetes.
PubMedID- 25661250 Liver fibrosis, primarily as a result of chronic damages to the liver such as chronic viral hepatitis and fatty liver diseases associated with obesity, is a worldwide burden 1–3.
PubMedID- 21841322 We hypothesized that dhea is involved in the pathophysiology of non-alcoholic fatty liver disease (nafld) often associated with obesity and insulin resistance.
PubMedID- 22821716 obesity is common in patients with end-stage liver disease of any cause.
PubMedID- 25866590 The development of high levels of liver fat predicts other metabolic complications, and nonalcoholic fatty liver disease is closely associated with obesity in many, but not all obese individuals [3].
PubMedID- 23935128 Objective: adipose tissue-derived factors link non-alcoholic fatty liver disease (nafld) with obesity, which has also been reported for circulating chemerin.

Page: 1 2